This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through June 3, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Pulmatrix (PULM) Catches Eye: Stock Jumps 6%
by Zacks Equity Research
Pulmatrix (PULM) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.
Corvus Pharmaceuticals (CRVS) Catches Eye: Stock Jumps 8.4%
by Zacks Equity Research
Corvus Pharmaceuticals (CRVS) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.
Seres Therapeutics (MCRB) in Focus: Stock Moves 10.8% Higher
by Zacks Equity Research
Seres Therapeutics (MCRB) saw a big move last session, as its shares jumped nearly 11% on the day, amid huge volumes.
Vaccinex (VCNX) Catches Eye: Stock Jumps 8.1%
by Zacks Equity Research
Vaccinex (VCNX) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.
Magenta (MGTA) Looks Good: Stock Adds 5.2% in Session
by Zacks Equity Research
Magenta (MGTA) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
CRISPR Therapeutics (CRSP) Surges: Stock Moves 6.8% Higher
by Zacks Equity Research
CRISPR Therapeutics (CRSP) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.
Zealand (ZEAL) Surges: Stock Moves 9.1% Higher
by Zacks Equity Research
Zealand (ZEAL) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.
Avid Bioservices (CDMO) Catches Eye: Stock Jumps 5.4%
by Zacks Equity Research
Avid Bioservices (CDMO) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
Ascendis Submits BLA to FDA for TransConhGH in Pediatric GHD
by Zacks Equity Research
Ascendis Pharma (ASND) submits BLA to the FDA for TransConhGH for the treatment of pediatric growth hormone deficiency.
VBI Vaccines (VBIV) in Focus: Stock Moves 8.3% Higher
by Zacks Equity Research
VBI Vaccines (VBIV) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.
AquaBounty (AQB) Catches Eye: Stock Jumps 8.9%
by Zacks Equity Research
AquaBounty (AQB) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.
BeyondSpring (BYSI) Catches Eye: Stock Jumps 10.9%
by Zacks Equity Research
BeyondSpring (BYSI) saw a big move last session, as its shares jumped nearly 11% on the day, amid huge volumes.
Precigen (PGEN) Soars: Stock Adds 9.4% in Session
by Zacks Equity Research
Precigen (PGEN) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.
Aeglea BioTherapeutics (AGLE) Catches Eye: Stock Jumps 5.1%
by Zacks Equity Research
Aeglea BioTherapeutics (AGLE) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
Why Applied Therapeutics (APLT) Stock Might be a Great Pick
by Zacks Equity Research
Applied Therapeutics (APLT) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Selecta Biosciences (SELB) in Focus: Stock Moves 7.4% Higher
by Zacks Equity Research
Selecta Biosciences (SELB) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.
Applied Therapeutics Inc. (APLT) Moves to Strong Buy: Rationale Behind the Upgrade
by Zacks Equity Research
Applied Therapeutics Inc. (APLT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Is Applied Therapeutics (APLT) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (APLT) Outperforming Other Medical Stocks This Year?
New Strong Buy Stocks For June 17th
by Tirthankar Chakraborty
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List today:
The Zacks Analyst Blog Highlights: Onconova Therapeutics, Abeona Therapeutics, Proteostasis Therapeutics, Applied Therapeutics and Ennis
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Onconova Therapeutics, Abeona Therapeutics, Proteostasis Therapeutics, Applied Therapeutics and Ennis
5 Top-Ranked Stocks Beating the Market at Midway Q1
by Sweta Killa
Better-than-expected earnings, positive development in the U.S.-China trade relationship, China stimulus measures, easing policies and slew of upbeat economic data buoyed the stocks.
US Dollar Flexes Muscles Against Other Currencies: 5 Winners
by Tirthankar Chakraborty
The US dollar drew support from a healthy domestic economy, and Fed's cautiously optimistic stance about holding interest rates despite the coronavirus outbreak.
Applied Therapeutics Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor Applied Therapeutics.
Applied Therapeutics Up on Positive Galactosemia Study Data
by Zacks Equity Research
Applied Therapeutics (APLT) soars on positive top-line results from the mid-stage study in adult Galactosemia patients on pipeline candidate, AT-007.
Company News for Jan 9, 2020
by Zacks Equity Research
Companies In The News Are: LTHM, NEWA, APLT, WBA